The Discovery of Anandamide — Your Brain's Own Cannabis Molecule
Isolation and structure of a brain constituent that binds to the cannabinoid receptor
In 1992, researchers in Jerusalem isolated a molecule from pig brains that binds the same receptor as THC — proving the brain makes its own version of cannabis, a finding that transformed neuroscience.
By 1990, neuroscientists had a problem they couldn't ignore. The cannabinoid receptor — CB1 — had been cloned, mapped, and shown to be one of the most abundant receptors in the human brain. More common than receptors for serotonin, dopamine, or opioids. Clearly, evolution had gone to enormous trouble to build this system.
But the brain didn't evolve cannabinoid receptors so that humans could smoke marijuana. Something inside the body had to be making its own version of THC. Nobody had ever seen it. But it had to exist.
The Question That Demanded an Answer
The logic was inescapable, and it followed directly from the isolation of THC twenty-eight years earlier.
This wasn't speculative. In pharmacology, every receptor discovered to date had turned out to have an endogenous ligand — a molecule the body makes to activate it. Opioid receptors had endorphins. Benzodiazepine receptors had neurosteroids. The cannabinoid receptor had to have something.
Finding it became the most important open question in cannabinoid science.
Three Countries, One Lab
The team that answered the question converged in Raphael Mechoulam's laboratory at the Hebrew University of Jerusalem — the same lab where THC had been characterized nearly three decades earlier.
William Devane was an American molecular pharmacologist who had already made his mark. In 1988, working in Allyn Howlett's lab at St. Louis University, he had co-discovered the cannabinoid receptor binding site — proving that THC acts through specific receptors rather than simply disrupting cell membranes. Having found the lock, Devane moved to Jerusalem specifically to find the key.
Lumír Hanuš was a Czech analytical chemist with the technical skills to isolate vanishingly small quantities of lipid compounds from biological tissue. He would perform the actual hands-on isolation work.
Raphael Mechoulam — now sixty-two, twenty-eight years past his THC breakthrough — orchestrated the project. He had spent three decades building the knowledge base that made this hunt possible.
“It was me who then isolated the compound in the brain, but he was running various tests to assess its activity, and I wouldn't have been able to do that without him, so it was our teamwork.”
— Lumír Hanuš
Hebrew University of Jerusalem
On his collaboration with William Devane
Searching Pig Brains
The method was conceptually simple but technically brutal. Take brain tissue, extract every lipid in it, and test each fraction for the ability to bind the cannabinoid receptor. Whatever sticks is your candidate.
The compound they isolated was unlike any known neurotransmitter. It wasn't an amino acid like glutamate or GABA. It wasn't an amine like dopamine or serotonin. It was a fatty acid amide — a lipid. This was unexpected. The idea that a greasy lipid molecule could transmit signals between brain cells struck many neuroscientists as implausible.
It would take years for the field to fully accept it.
Ananda — Bliss
On March 24, 1992, Hanuš isolated the compound. It needed a name.
Mechoulam wanted something fitting. The molecule was produced by the brain, bound the same receptor as the plant compound that had fascinated humanity for millennia, and appeared to be involved in pleasure and reward. He considered a Hebrew name.
"We looked for a Hebrew name," he later recalled, "but as you may well be aware, Jews are not very happy. We have a lot of words for being down and so on, but not so many words for extreme joy."
They turned to Sanskrit instead. Ananda — bliss, joy, delight. The compound became anandamide: the bliss amide.
A Two-Sentence Answer to a 28-Year Question
The paper was published December 18, 1992, in Science — one of the two most prestigious scientific journals in the world. Four pages. Ten authors from Israel, the United States, and the United Kingdom.
#1
ranked paper in bibliometric analyses of endocannabinoid and cannabinoid research. The keyword 'anandamide' appears in 17 of the 100 most-cited papers in the field.
This single discovery — that the brain makes its own cannabinoid — launched more subsequent research than any other finding in cannabis science.
PMC7815052, Bibliometric analysis of cannabinoid research (2021)
The paper's conclusion, stripped to its essence: your brain makes its own cannabis. Not THC exactly — something structurally different that fits the same receptor. But the implication was staggering. The entire cannabinoid receptor system — the most abundant receptor family in the brain — existed not for marijuana but for the body's own signaling network.
The endocannabinoid system had been found.
Not Quite THC
The "bliss molecule" label caught on with the public. But it oversells what anandamide actually is, and confuses how it works.
Myth vs. Reality
Anandamide is the brain's version of THC — a bliss molecule that makes you feel high.
Anandamide binds the same receptor as THC but is structurally completely different, much weaker, and disappears from the brain in seconds. It's a regulatory signal, not a euphoria switch.
The Evidence
THC is a terpenophenolic compound from the cannabis plant. Anandamide is a fatty acid amide made from cell membrane components. At the receptor, anandamide is a partial agonist (weak activator) while THC produces stronger activation. Anandamide's half-life is seconds to minutes due to rapid breakdown by the enzyme FAAH — compared to THC, which persists for hours. Calling anandamide a 'bliss molecule' is like calling insulin a 'sugar molecule' because it's involved in blood sugar regulation.
Sagheddu et al. (2019), PMC6460372; Devane et al. (1992), Science
The differences matter. When you consume cannabis, you flood your brain with a potent, long-lasting CB1 agonist. When your brain releases anandamide, it's a brief, precisely targeted signal — more like a whisper than a shout. This is why daily cannabis use can disrupt the endocannabinoid system: chronic THC overwhelms the subtle signaling that anandamide provides. It's also why withdrawal symptoms occur — the brain has downregulated its response to both THC and its own anandamide.
The Day Anandamide Almost Died
The discovery was not universally celebrated. In 1996, anandamide came dangerously close to being discredited.
The problem was conceptual and technical. The idea that a lipid — essentially a fat molecule — could function as a neurotransmitter was deeply counterintuitive to many neuroscientists. Classical neurotransmitters are stored in vesicles and released into synapses. Lipids don't behave that way. They're part of cell membranes. How could a membrane component also be a signaling molecule?
Replication was difficult. Anandamide is produced in tiny quantities and destroyed almost instantly by FAAH. Measuring it accurately required techniques that were still being developed. Some labs couldn't reproduce key findings. Questions swirled about whether measured anandamide levels were genuine signals or extraction artifacts.
What rescued anandamide's reputation was partly the discovery of 2-arachidonoylglycerol (2-AG) in 1995 — a second endocannabinoid that was more abundant and easier to detect — and partly the development of FAAH inhibitors that allowed researchers to study what happens when anandamide levels rise in a controlled way. Both confirmed the core insight: the brain really does produce cannabinoid receptor ligands.
Two Endocannabinoids, Two Roles
The discovery of 2-AG three years later revealed that anandamide was only half the picture. The two molecules were initially treated as interchangeable, but they turned out to be fundamentally different.
They're not competitors — they're complementary. 2-AG handles most of the moment-to-moment synaptic signaling. Anandamide appears to play a more modulatory role, setting baseline tone for mood, stress resilience, and pain perception. Both are essential. Both are disrupted by chronic cannabis use.
What Anandamide Unlocked
The 1992 paper didn't just identify a molecule. It proved a system exists. And that system turned out to be everywhere.
From Pig Brains to Runner's High
Thirty years after its discovery, anandamide has gone from an obscure lipid isolated from pig brain tissue to a molecule at the center of multiple lines of medical research.
The runner's high — that feeling of euphoria and reduced pain during sustained exercise — was long attributed to endorphins. But endorphin molecules are too large to cross the blood-brain barrier. In 2012, researchers showed that exercise dramatically increases circulating anandamide levels, and that anandamide can cross into the brain. The bliss of running is, at least partly, the bliss of anandamide.
Anandamide has even been found in chocolate — cocoa contains both anandamide itself and two compounds that slow its degradation by FAAH. (Before you get excited: the quantities are far too small to produce any meaningful cannabinoid receptor activation. Chocolate does not get you high via anandamide.)
More consequentially, drugs that boost anandamide by inhibiting FAAH — the enzyme that destroys it — are being developed for anxiety, depression, PTSD, and chronic pain. Rather than flooding the brain with an external cannabinoid like THC, these drugs amplify the brain's own signaling. It's a precision approach that traces directly back to knowing anandamide exists.
“I have spent most of my life decoding the mysteries to be found within this incredible plant.”
— Raphael Mechoulam
Hebrew University of Jerusalem
Reflecting on the journey from THC in 1964 to the endocannabinoid system — a journey that passed through this paper
Frequently Asked Questions
Cite this study
Devane, William A.; Hanus, Lumir; Breuer, Aviva; Pertwee, Roger G.; Stevenson, Lesley A.; Griffin, Graeme; Gibson, Dale; Mandelbaum, Arnon; Etinger, Alexander; Mechoulam, Raphael. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946-1949. https://doi.org/10.1126/science.1470919